Here are some things to think about
The use of lorcaserin is associated with an additional annual weight loss of about 3.23.6 kg as well as improvements in metabolic parameters including blood pressure (systolic, 0.61 mmHg
They can assess whether your symptoms are related to the medication or indicative of an underlying condition that needs attention
Angermayer runs Apeiron Investment Group, which has invested heavily in biotech and longevity
Given their glucose-lowering effects, GLP-1s have become standard of care for type 2 diabetes, supplanting other medication classes such as sulfonylureas.2 In 2023, GLP-1s represented 63% of diabetes spend, up from 38% in 2020.2 While diabetes GLP-1s will continue to account for a greater portion of spend compared to obesity, costs related to GLP-1s prescribed for obesity are expected to grow at a faster rate over the next 3 years
The long-acting effect of TRESIBA may delay recovery from hypoglycemia compared to shorter-acting insulins